Greenberg S B, Faerber E N, Radke J L, Aspinall C L, Adams R C, Mercer-Wilson D D
Department of Radiology, St. Christopher's Hospital for Children, Philadelphia, PA 19134.
AJR Am J Roentgenol. 1994 Jul;163(1):165-8. doi: 10.2214/ajr.163.1.8010205.
The purpose of this prospective study was to evaluate the safety and efficacy of thioridazine as an adjunct to chloral hydrate sedation when children undergoing MR imaging are difficult to sedate.
All 87 children in the study either could not be sedated with chloral hydrate alone or were mentally retarded. Thioridazine (2-4 mg/kg) was administered orally 2 hr before and chloral hydrate (50-100 mg/kg) was administered orally 30 min before the 104 MR examinations. All children were monitored by continuous pulse oximetry. All images were individually evaluated by pediatric radiologists and were graded acceptable if they contained only minimal motion artifact or no motion artifact. Studies were considered successful only when 95% or more of the images were acceptable.
MR imaging was successful in 93 (89%) of 104 examinations. The success rate for children entered into the study because of prior failure of chloral hydrate sedation was not significantly different from the success rate for children with mental retardation. A tendency for increasing failure rate with age was not significant. No serious complications occurred during the study. The most common adverse reaction, transient reduced oxygen saturation, was seen in five children. Other adverse effects encountered were vomiting in four children, hyperactivity in two children, transient tachycardia in one child, and prolonged sedation in one child. No child required hospitalization because of an adverse reaction to sedation.
The study indicates that thioridazine is a safe and effective adjunct to chloral hydrate when a child undergoing MR imaging is difficult to sedate.
这项前瞻性研究的目的是评估在接受磁共振成像(MR)检查时难以镇静的儿童中,硫利达嗪作为水合氯醛镇静辅助药物的安全性和有效性。
研究中的87名儿童要么单独使用水合氯醛无法达到镇静效果,要么存在智力障碍。在104次MR检查前2小时口服硫利达嗪(2 - 4mg/kg),并在检查前30分钟口服水合氯醛(50 - 100mg/kg)。所有儿童均通过持续脉搏血氧饱和度监测。所有图像均由儿科放射科医生单独评估,若仅包含最小程度的运动伪影或无运动伪影,则评为可接受。仅当95%或更多图像可接受时,研究才被视为成功。
104次检查中有93次(89%)MR成像成功。因先前水合氯醛镇静失败而纳入研究的儿童的成功率与智力障碍儿童的成功率无显著差异。随年龄增长失败率增加的趋势不显著。研究期间未发生严重并发症。最常见的不良反应是5名儿童出现短暂性血氧饱和度降低。其他不良反应包括4名儿童呕吐、2名儿童多动、1名儿童短暂性心动过速以及1名儿童镇静时间延长。没有儿童因镇静不良反应而需要住院治疗。
该研究表明,对于接受MR成像时难以镇静的儿童,硫利达嗪是水合氯醛安全有效的辅助药物。